BACKGROUND AND PURPOSE: Medial temporal lobe atrophy (MTA) is a hallmark of Alzheimer disease (AD). Its progression is often seen during the course of AD, but its frequency and risk factors remain unclear. METHODS: We investigated MTA in 35 patients with AD from whom sequential magnetic resonance imaging scans were available. White matter lesions (WML; for the periventricular [PV] and subcortical [SC] regions separately) and MTA were rated semiquantitatively. RESULTS: In approximately two thirds of all patients, progression of MTA was found. The mean MTA progression was 0.8 (standard deviation: 0.5) and 0.3 (standard deviation: 0.4) for patients with or without PVWML at baseline (P=0.01). Patients who showed progression of PVWML over the course of their disease had a significantly higher mean progression of MTA than those without PVWML progression (0.9 [SD: 0.4]) and 0.4 [SD: 0.5]; P=0.01). Patients with PVWML at baseline had a 40-fold increased risk for progression of MTA compared with those without baseline PVWML (odds ratio=40.0, 95% CI=1.3 to 1.2x10(3), P=0.03). Patients with progression of PVWML during the course of the disease had an increased risk for MTA progression (odds ratio=3.7 per unit increase of progression of PVWML, 95% CI=1.1 to 12.9, P=0.04). There was higher risk for progression of MTA for those with progression of PVWML than those without (odds ratio=10.9, 95% CI=1.0 to 122.5, P=0.05). This was not found for SCWML. CONCLUSIONS: Our findings suggest that the presence and the progression of WML are associated with progression of MTA in AD. WML may be a predictor of the course of the disease and a potential treatment target in AD.
BACKGROUND AND PURPOSE: Medial temporal lobe atrophy (MTA) is a hallmark of Alzheimer disease (AD). Its progression is often seen during the course of AD, but its frequency and risk factors remain unclear. METHODS: We investigated MTA in 35 patients with AD from whom sequential magnetic resonance imaging scans were available. White matter lesions (WML; for the periventricular [PV] and subcortical [SC] regions separately) and MTA were rated semiquantitatively. RESULTS: In approximately two thirds of all patients, progression of MTA was found. The mean MTA progression was 0.8 (standard deviation: 0.5) and 0.3 (standard deviation: 0.4) for patients with or without PVWML at baseline (P=0.01). Patients who showed progression of PVWML over the course of their disease had a significantly higher mean progression of MTA than those without PVWML progression (0.9 [SD: 0.4]) and 0.4 [SD: 0.5]; P=0.01). Patients with PVWML at baseline had a 40-fold increased risk for progression of MTA compared with those without baseline PVWML (odds ratio=40.0, 95% CI=1.3 to 1.2x10(3), P=0.03). Patients with progression of PVWML during the course of the disease had an increased risk for MTA progression (odds ratio=3.7 per unit increase of progression of PVWML, 95% CI=1.1 to 12.9, P=0.04). There was higher risk for progression of MTA for those with progression of PVWML than those without (odds ratio=10.9, 95% CI=1.0 to 122.5, P=0.05). This was not found for SCWML. CONCLUSIONS: Our findings suggest that the presence and the progression of WML are associated with progression of MTA in AD. WML may be a predictor of the course of the disease and a potential treatment target in AD.
Authors: Hee Jin Kim; Jeonghun Kim; Hanna Cho; Byoung Seok Ye; Cindy W Yoon; Young Noh; Geon Ha Kim; Jae Hong Lee; Jae Seung Kim; Yearn Seong Choe; Kyung-Han Lee; Chang-Hun Kim; Sang Won Seo; Michael W Weiner; Duk L Na; Joon-Kyung Seong Journal: PLoS One Date: 2013-10-10 Impact factor: 3.240
Authors: T M Polvikoski; E C W van Straaten; F Barkhof; R Sulkava; H J Aronen; L Niinistö; M Oinas; P Scheltens; T Erkinjuntti; R N Kalaria Journal: Neurology Date: 2010-11-03 Impact factor: 9.910
Authors: Anouk G W van Norden; Karlijn F de Laat; Ilma Fick; Inge W M van Uden; Lucas J B van Oudheusden; Rob A R Gons; David G Norris; Marcel P Zwiers; Roy P C Kessels; Frank-Erik de Leeuw Journal: Hum Brain Mapp Date: 2011-03-09 Impact factor: 5.038
Authors: I W M van Uden; A M Tuladhar; H M van der Holst; E M C van Leijsen; A G W van Norden; K F de Laat; L C A Rutten-Jacobs; D G Norris; J A H R Claassen; E J van Dijk; R P C Kessels; F-E de Leeuw Journal: Hum Brain Mapp Date: 2015-10-15 Impact factor: 5.038
Authors: D H Salat; D S Tuch; A J W van der Kouwe; D N Greve; V Pappu; S Y Lee; N D Hevelone; A K Zaleta; J H Growdon; S Corkin; B Fischl; H D Rosas Journal: Neurobiol Aging Date: 2010-02 Impact factor: 4.673
Authors: Michel Bilello; Jimit Doshi; S Ali Nabavizadeh; Jon B Toledo; Guray Erus; Sharon X Xie; John Q Trojanowski; Xiaoyan Han; Christos Davatzikos Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Wandana Nanhoe-Mahabier; Karlijn F de Laat; Jasper E Visser; Jan Zijlmans; Frank-Erik de Leeuw; Bastiaan R Bloem Journal: Nat Rev Neurol Date: 2009-09-01 Impact factor: 42.937